Thank Otezla for Amgen's Q3 Revenue and Earnings Beats

[cafead]

via It was beginning to look like a decent year for Amgen (NASDAQ:AMGN) after the company blew past Wall Street estimates with its second-quarter results three months ago. Since then, though, Amgen has come under congressional scrutiny for its drug pricing. The stock has also given up all of its gains and then some.

article source